Related Experiment Video
Updated: Aug 24, 2025
05:39
Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
1.7K
Evaluating new treatments for anaplastic thyroid cancer
Andrés Coca-Pelaz1, Juan P Rodrigo1, Fernando Lopez1
1Department of Otolaryngology, Hospital Universitario Central de Asturias, University of Oviedo, ISPA, IUOPA, CIBERONC, Oviedo, Spain.
Expert Review of Anticancer Therapy
|October 25, 2022
Summary
Anaplastic thyroid cancer (ATC) treatment is evolving with personalized medicine. Targeted therapies like dabrafenib and trametinib show promise for specific mutations, improving survival and quality of life.
Area of Science:
- Oncology
- Molecular Medicine
- Genetics
Background:
- Anaplastic thyroid cancer (ATC) is a rare and aggressive malignancy with a poor prognosis.
- The American Thyroid Association (ATA) has released updated guidelines for ATC management.
- Current treatment strategies are limited, necessitating novel therapeutic approaches.
Approach:
- This review synthesizes recent findings from clinical trials published within the last five years.
- It summarizes ongoing clinical trials investigating new therapeutic options for ATC.
- The focus is on personalized medicine based on tumor genetic profiles.
Key Points:
- Targeted therapies, such as dabrafenib and trametinib, demonstrate efficacy in ATC harboring the BRAF V600E mutation.
- Individualized treatment strategies utilizing drug combinations targeting distinct molecular pathways are being explored.
- New targeted therapies have led to improved survival rates and quality of life by reducing local disease progression.
Conclusions:
- Personalized medicine, guided by tumor genetics, represents a significant advancement in ATC treatment.
- While survival remains a challenge, targeted therapies offer improved outcomes and better quality of life for patients.
- Further research into novel drug combinations and treatment strategies is crucial for improving long-term survival in ATC.
